2010版《慢性乙型肝炎防治指南》解读——慢性乙型肝炎治疗目标和适应证

李海; 贾继东

2010版《慢性乙型肝炎防治指南》解读——慢性乙型肝炎治疗目标和适应证

李海,
贾继东

首都医科大学附属北京友谊医院肝病中心

详细信息

中图分类号: R512.62
计量
- 文章访问数: 3204
- HTML全文浏览量: 10
- PDF下载量: 823
- 被引次数: 0
出版历程
- 出版日期: 2011-08-20

Interpretation of the guideline on prevention and treatment for chronic hepatitis B (2010 version) -the goals and indications for chronic hepatitis B treatment

Li Hai,
Jia JiDong

摘要

摘要: <正>中华医学会肝病学分会和感染病分会于2010年12月10日发布了2010年版《慢性乙型肝炎防治指南》(以下简称本指南)[1]。在2005年版指南的基础上[2],本指南吸收了近年国内外有关乙型肝炎预防、诊断及治疗的最新研究成果,按照循证医学原则,全
- 肝炎,乙型,慢性 /
- 指南
- hepatitis B /
- chronic

HTML全文

参考文献(18)

[1]贾继东, 李兰娟.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, (1) :113-128.

[2]中华医学会肝病学会.慢性乙型肝炎防治指南[J].临床肝胆病杂志, 2006, (1) :3-15.

[3]Chen YC, Chu CM, Yeh CT, et al.Natural course following theonset of cirrhosis in patients with chronic hepatitis B:a long-termfollow-up study[J].Hepatol Int, 2007, 1 (1) :267-273.

[4]Liaw YF.Natural history of chronic hepatitis B virus infection andlong-term outcome under treatment[J].Liver Int, 2009, 29 (Sup-pl 1) :100-107.

[5]Yuen MF, Wong DK, Fung J, et al.HBsAg Seroclearance inchronic hepatitis B in Asian patients:replicative level and risk ofhepatocellular carcinoma[J].Gastroenterology, 2008, 135 (4) :1192-1199.

[6]Lok AS, McMahon BJ.Chronic hepatitis B:update 2009[J].Hepatol-ogy, 2009, 50 (3) :661-697.

[7]European Association For The Study Of The Liver.EASL Clinical Prac-tice Guidelines:management of chronic hepatitis B[J].J Hepatol, 2009, 50 (2) :227-242.

[8]Hui CK, Leung N, Yuen ST, et al.Natural history and diseaseprogression in Chinese chronic hepatitis B patients in immune-tol-erant phase[J].Hepatology, 2007, 46 (2) :395-401.

[9]Chu CM, Liaw YF.HBsAg seroclearance in asymptomatic carriers ofhigh endemic areas:appreciably high rates during a long-term follow-up[J].Hepatology, 2007, 45 (5) :1187-1192.

[10]Chen CJ, Yang HI, Iloeje UH.Hepatitis B virus DNA levels andoutcomes in chronic hepatitis B[J].Hepatology, 2009, 49 (5 Sup-pl) :S72-84.

[11]Villeneuve JP, Condreay LD, Willems B, et al.Lamivudine treat-ment for decompensated cirrhosis resulting from chronic hepatitis B[J].Hepatology, 2000, 31 (1) :207-210.

[12]Perrillo RP, Wright T, Rakela J, et al.A multicenter United States-Canadian trial to assess lamivudine monotherapy be-fore and after liver transplantation for chronic hepatitis B[J].Hepa-tology, 2001, 33 (2) :424-432.

[13]Hann HW, Fontana RJ, Wright T, et al.A United States compas-sionate use study of lamivudine treatment in nontransplantation can-didates with decompensated hepatitis B virus-related cirrhosis[J].Liver Transpl, 2003, 9 (1) :49-56.

[14]Lo CM, Liu CL, Lau GK, et al.Liver transplantation for chronichepatitis B with lamivudine-resistant YMDD mutant using add-onadefovir dipivoxil plus lamivudine[J].Liver Transpl, 2005, 11 (7) :807-813.

[15]Koda M, Nagahara T, Matono T, et al.Nucleotide analogs for pa-tients with HBV-related hepatocellular carcinoma increase the sur-vival rate through improved liver function[J].Intern Med, 2009, 48 (1) :11-17.

[16]Keeffe EB, Dieterich DT, Han SH, et al.A treatment algorithm forthe management of chronic hepatitis B virus infection in the UnitedStates:an update[J].Clin Gastroenterol Hepatol, 2006, 4 (8) :936-962.

[17]Chu CM, Liaw YF.Hepatitis B virus-related cirrhosis:naturalhistory and treatment[J].Semin Liver Dis, 2006, 26 (2) :142-152.

[18]Tai DI, Chen CH, Chang TT, et al.Eight-year nationwide surviv-al analysis in relatives of patients with hepatocellular carcinoma:role of viral infection[J].J Gastroenterol Hepatol, 2002, 17 (6) :682-689.

施引文献

资源附件(0)

访问统计